CONSORT-EHEALTH (V 1.6.1) -Submission/Publication Form

The CONSORT-EHEALTH checklist is intended for authors of randomized trials evaluating web-based and Internet-based applications/interventions, including mobile interventions, electronic games (incl multiplayer games), social media, certain telehealth applications, and other interactive and/or networked electronic applications. Some of the items (e.g. all subitems under item 5 - description of the intervention) may also be applicable for other study designs.

The goal of the CONSORT EHEALTH checklist and guideline is to be a) a guide for reporting for authors of RCTs, b) to form a basis for appraisal of an ehealth trial (in terms of validity)

CONSORT-EHEALTH items/subitems are MANDATORY reporting items for studies published in the Journal of Medical Internet Research and other journals / scientific societies endorsing the checklist.

Items numbered 1., 2., 3., 4a., 4b etc are original CONSORT or CONSORT-NPT (nonpharmacologic treatment) items. Items with Roman numerals (i., ii, iii, iv etc.) are CONSORT-EHEALTH extensions/clarifications.

As the CONSORT-EHEALTH checklist is still considered in a formative stage, we would ask that you also RATE ON A SCALE OF 1-5 how important/useful you feel each item is FOR THE PURPOSE OF THE CHECKLIST and reporting guideline (optional).

Mandatory reporting items are marked with a red *.

In the textboxes, either copy & paste the relevant sections from your manuscript into this form - please include any quotes from your manuscript in QUOTATION MARKS, or answer directly by providing additional information not in the manuscript, or elaborating on why the item was not relevant for this study.

CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form

YOUR ANSWERS WILL BE PUBLISHED AS A SUPPLEMENTARY FILE TO YOUR PUBLICATION IN JMIR AND ARE CONSIDERED PART OF YOUR PUBLICATION (IF ACCEPTED). Please fill in these questions diligently. Information will not be copyedited, so please use proper spelling and grammar, use correct capitalization, and avoid abbreviations.

DO NOT FORGET TO SAVE AS PDF _AND_ CLICK THE SUBMIT BUTTON SO YOUR ANSWERS ARE IN OUR DATABASE !!!

Citation Suggestion (if you append the pdf as Appendix we suggest to cite this paper in the caption):

Eysenbach G, CONSORT-EHEALTH Group

CONSORT-EHEALTH: Improving and Standardizing Evaluation Reports of Web-based and Mobile Health Interventions

J Med Internet Res 2011;13(4):e126

URL: http://www.jmir.org/2011/4/e126/

doi: 10.2196/jmir.1923 PMID: 22209829

* Required

Your name *

First Last

Ella Kurz

Primary Affiliation (short), City, Country *

University of Toronto, Toronto, Canada

Australian National University

Your e-mail address *

abc@gmail.com

ella.kuez@anu.edu.au

Title of your manuscript * Provide the (draft) title of your manuscript.

Efficacy of a Transdiagnostic Self-Help Internet Intervention for Reducing Depression, Anxiety, and Suicidal Ideation in Adults: Randomized Controlled Trial

Name of your App/Software/Intervention *

If there is a short and a long/alternate name, write the short name first and add the long name in brackets.

FitMindKit

Evaluated Version (if any) e.g. "V1", "Release 2017-03-01", "Version 2.0.27913"

Your answer

E

Language(s) *

What language is the intervention/app in? If multiple languages are available, separate by comma (e.g. "English, French")

English

URL of your Intervention Website or App

e.g. a direct link to the mobile app on app in appstore (itunes, Google Play), or URL of the website. If the intervention is a DVD or hardware, you can also link to an Amazon page.

Your answer

URL of an image/screenshot (optional)

Your answer

Accessibility *

Can an enduser access the intervention presently?

- access is free and open
- access only for special usergroups, not open
- access is open to everyone, but requires payment/subscription/in-app purchases
- app/intervention no longer accessible
- Other:

Primary Medical Indication/Disease/Condition *

e.g. "Stress", "Diabetes", or define the target group in brackets after the condition, e.g. "Autism (Parents of children with)", "Alzheimers (Informal Caregivers of)"

Mental health

Primary Outcomes measured in trial *

comma-separated list of primary outcomes reported in the trial

Depression symptoms

E

Secondary/other outcomes

Are there any other outcomes the intervention is expected to affect?

Anxiety symptoms, disability, and suicidal ideation.

Recommended "Dose" *

What do the instructions for users say on how often the app should be used?

- Approximately Daily
- Approximately Weekly
- Approximately Monthly
- Approximately Yearly
- "as needed"
- Other:

Approx. Percentage of Users (starters) still using the app as recommended after 3 months * unknown / not evaluated 0-10% 11-20% 21-30% 31-40% 41-50% 51-60% 61-70% 71%-80% 81-90% 91-100% Other:

- () yes: all primary outcomes were significantly better in intervention group vs control
- O partly: SOME primary outcomes were significantly better in intervention group vs control
- no statistically significant difference between control and intervention
- O potentially harmful: control was significantly better than intervention in one or more outcomes
- inconclusive: more research is needed
- Other:

Article Preparation Status/Stage *

At which stage in your article preparation are you currently (at the time you fill in this form)

- not submitted yet in early draft status
- not submitted yet in late draft status, just before submission
- submitted to a journal but not reviewed yet
- Submitted to a journal and after receiving initial reviewer comments
- submitted to a journal and accepted, but not published yet
-) published
- Other:

Journal *

If you already know where you will submit this paper (or if it is already submitted), please provide the journal name (if it is not JMIR, provide the journal name under "other")

- not submitted yet / unclear where I will submit this
- Journal of Medical Internet Research (JMIR)
- JMIR mHealth and UHealth
- JMIR Serious Games
- JMIR Mental Health
- JMIR Public Health
- JMIR Formative Research
- Other JMIR sister journal
- Other:


Is this a full powered effectiveness trial or a pilot/feasibility trial? *

- Pilot/feasibility
- Fully powered

Manuscript tracking number *

If this is a JMIR submission, please provide the manuscript tracking number under "other" (The ms tracking number can be found in the submission acknowledgement email, or when you login as author in JMIR. If the paper is already published in JMIR, then the ms tracking number is the four-digit number at the end of the DOI, to be found at the bottom of each published article in JMIR)

no ms number (yet) / not (yet) submitted to / published in JMIR



TITLE AND ABSTRACT

1a) TITLE: Identification as a randomized trial in the title

1a) Does your paper address CONSORT item 1a? *


I.e does the title contain the phrase "Randomized Controlled Trial"? (if not, explain the reason under "other")

yes

Other:

1a-i) Identify the mode of delivery in the title


Identify the mode of delivery. Preferably use "web-based" and/or "mobile" and/or "electronic game" in the title. Avoid ambiguous terms like "online", "virtual", "interactive". Use "Internet-based" only if Intervention includes non-web-based Internet components (e.g. email), use "computer-based" or "electronic" only if offline products are used. Use "virtual" only in the context of "virtual reality" (3-D worlds). Use "online" only in the context of "online support groups". Complement or substitute product names with broader terms for the class of products (such as "mobile" or "smart phone" instead of "iphone"), especially if the application runs on different platforms.



Does your paper address subitem 1a-i?*

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No



Does your paper address subitem 1a-ii?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not relevant as there were no other components

1a-iii) Primary condition or target group in the title

Mention primary condition or target group in the title, if any (e.g., "for children with Type I Diabetes") Example: A Web-based and Mobile Intervention with Telephone Support for Children with Type I Diabetes: Randomized Controlled Trial

| | 1 | 2 | 3 | 4 | 5 | |
|------------------------------|---|---|---|---|---|-----------|
| subitem not at all important | 0 | 0 | 0 | 0 | 0 | essential |

Does your paper address subitem 1a-iii? *

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes - 'in Adults'

1b) ABSTRACT: Structured summary of trial design, methods, results, and

conclusions

NPT extension: Description of experimental treatment, comparator, care providers, centers, and blinding status.

1b-i) Key features/functionalities/components of the intervention and

comparator in the METHODS section of the ABSTRACT

Mention key features/functionalities/components of the intervention and comparator in the abstract. If possible, also mention theories and principles used for designing the site. Keep in mind the needs of systematic reviewers and indexers by including important synonyms. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)



Does your paper address subitem 1b-i? *

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes ';This randomized controlled trial (RCT) tests the effectiveness of the video-

based transdiagnostic intervention

FitMindKit in reducing depression symptoms (primary outcome), anxiety

symptoms, disability, and suicidal ideation, relative to

an attention-matched control condition called HealthWatch.'

1b-ii) Level of human involvement in the METHODS section of the ABSTRACT

Clarify the level of human involvement in the abstract, e.g., use phrases like "fully automated" vs. "therapist/nurse/care provider/physician-assisted" (mention number and expertise of providers involved, if any). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

| | 1 | 2 | 3 | 4 | 5 | |
|------------------------------|---|---|---|---|---|-----------|
| subitem not at all important | 0 | 0 | 0 | 0 | 0 | essential |

Does your paper address subitem 1b-ii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study


Yes - ' Participants were assessed at baseline and at 4 weeks postbaseline. To

maintain the ecological validity

of the trial, participants completed brief assessments and interventions without direct researcher contact or incentives.'

1b-iii) Open vs. closed, web-based (self-assessment) vs. face-to-face assessments in the METHODS section of the ABSTRACT

Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic or a closed online user group (closed usergroup trial), and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment). Clearly say if outcomes were self-assessed through questionnaires (as common in web-based trials). Note: In traditional offline trials, an open trial (open-label trial) is a type of clinical trial in which both the researchers and participants know which treatment is being administered. To avoid confusion, use "blinded" or "unblinded" to indicated the level of blinding instead of "open", as "open" in web-based trials usually refers to "open access" (i.e. participants can self-enrol). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)



Does your paper address subitem 1b-iii?


Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes - 'Participants (n=1986) were

recruited through the web using social media advertisements, screened for psychological distress, and then randomized to receive one of two 4-week programs: FitMindKit (12-module psychotherapy intervention) or HealthWatch (12-module program providing general health information). Participants were assessed at baseline and at 4 weeks postbaseline. To maintain the ecological validity of the trial, participants completed brief assessments and interventions without direct researcher contact or incentives'

1b-iv) RESULTS section in abstract must contain use data

Report number of participants enrolled/assessed in each group, the use/uptake of the intervention (e.g., attrition/adherence metrics, use over time, number of logins etc.), in addition to primary/secondary outcomes. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)



Does your paper address subitem 1b-iv?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study


Effect sizes of main outcome and some secondary outcomes reported. 'Mixed model repeated-measures analyses of variance demonstrated that FitMindKit significantly improved depression

symptoms (F1,701.7=3.97; P=.047), along with panic symptoms (F1,706.5=5.59; P=.02) and social anxiety symptoms (F1,680.0=12.37;

P<.001), relative to the attention control condition. There were no significant effects on other outcomes.'

1b-v) CONCLUSIONS/DISCUSSION in abstract for negative trials

Conclusions/Discussions in abstract for negative trials: Discuss the primary outcome - if the trial is negative (primary outcome not changed), and the intervention was not used, discuss whether negative results are attributable to lack of uptake and discuss reasons. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)



Does your paper address subitem 1b-v?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Trial not negative

INTRODUCTION

2a) In INTRODUCTION: Scientific background and explanation of rationale

2a-i) Problem and the type of system/solution

Describe the problem and the type of system/solution that is object of the study: intended as stand-alone intervention vs. incorporated in broader health care program? Intended for a particular patient population? Goals of the intervention, e.g., being more cost-effective to other interventions, replace or complement other solutions? (Note: Details about the intervention are provided in "Methods" under 5)




Does your paper address subitem 2a-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes - 'Depression and anxiety are common mental disorders that account for significant global disease and disability burden [1]. Despite significant personal, interpersonal, social, educational, and vocational impacts of these disorders, only one in 3 people with a mental health problem seeks help from a health professional [2-4]. Those who engage in professional treatment. typically delay seeking help for years or decades [5]. Cost of treatment, stigma, lack of knowledge, and low perceived need for treatment are commonly cited as barriers to seeking mental health help [6-8]. Internet-based, self-guided mental health interventions are able to mitigate some of these barriers and have been shown to be effective, efficient, and cost-effective in the prevention and treatment of many common mental disorders [9-11]. The high rate of comorbidity between depression, anxiety, and other mental health problems represents another significant challenge for help seeking and treatment, as it is often related to an increase in the severity and chronicity of symptoms [12,13]. One solution to the challenge of treating comorbid mental health problems is the use of transdiagnostic treatment approaches.

2a-ii) Scientific background, rationale: What is known about the (type of) system

Scientific background, rationale: What is known about the (type of) system that is the object of the study (be sure to discuss the use of similar systems for other conditions/diagnoses, if appropiate), motivation for the study, i.e. what are the reasons for and what is the context for this specific study, from which stakeholder viewpoint is the study performed, potential impact of findings [2]. Briefly justify the choice of the comparator.



Does your paper address subitem 2a-ii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes - 'Transdiagnostic treatments are typically based on the principles of cognitive behavioral therapy (CBT), which is an efficacious treatment approach for multiple mood and anxiety disorders [14,15]. Transdiagnostic treatments provide therapeutic content capable of targeting the common cognitive and behavioral processes that underlie the development and maintenance of multiple mental health disorders (eg, negative thinking patterns, avoidance, hyperarousal) and address symptoms that are common to multiple disorders (eg, sleep disturbance) [16,17].'

2b) In INTRODUCTION: Specific objectives or hypotheses


Does your paper address CONSORT subitem 2b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes - 'the objective of this trial was to test the effectiveness of FitMindKit in reducing symptoms of depression and anxiety, suicidal ideation, and disability, when delivered in a real-world setting.'

METHODS

3a) Description of trial design (such as parallel, factorial) including allocation ratio



Does your paper address CONSORT subitem 3a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes - 'A two-arm parallel RCT was conducted comparing an active intervention (FitMindKit) with an attention control condition (HealthWatch). The trial protocol is provided in Batterham et al [24].'

3b) Important changes to methods after trial commencement (such as eligibility criteria), with reasons


Does your paper address CONSORT subitem 3b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

N/A methods did not change after trial commencement

3b-i) Bug fixes, Downtimes, Content Changes

Bug fixes, Downtimes, Content Changes: ehealth systems are often dynamic systems. A description of changes to methods therefore also includes important changes made on the intervention or comparator during the trial (e.g., major bug fixes or changes in the functionality or content) (5-iii) and other "unexpected events" that may have influenced study design such as staff changes, system failures/downtimes, etc. [2].



Does your paper address subitem 3b-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

N/A this issues did not arise

4a) Eligibility criteria for participants

Does your paper address CONSORT subitem 4a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes - 'To be eligible for the trial, participants were required to be aged 18 years and older and had moderate psychological distress as measured by the Distress Questionnaire-5 (DQ5) [29]. The DQ5 is a measure of psychological distress and consists of 5 items that assess the symptoms of common mental disorders. Participants were asked to endorse the frequency of each item over the last 30 days on a 5-point scale, ranging from never to always, with scores ranging from 5 to 25. In this study, the categories of DQ5 scores were no or low psychological distress (score of 5-7), moderate psychological distress/risk of a mental disorder (score of 8-17), and high-risk/probable clinical symptoms of a mental disorder (score of 18-25). These cut points were selected based on percentiles from existing population-based data [29]. Participants aged 18 years and older and who scored in the moderate risk category (score of 8-17) on the DQ5 were eligible for the trial, as a web-based self-guided mental health program is likely to be the most suitable for this group. Those in the low-risk category were provided with feedback and resources to access if their symptoms changed. Those in the high-risk category were strongly encouraged to seek help from a health professional and provided contact details for face-to-face, telephone-based, and web-based mental health resources and services.



Does your paper address subitem 4a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

4a-ii) Open vs. closed, web-based vs. face-to-face assessments:


Open vs. closed, web-based vs. face-to-face assessments: Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic, and clarify if this was a purely webbased trial, or there were face-to-face components (as part of the intervention or for assessment), i.e., to what degree got the study team to know the participant. In online-only trials, clarify if participants were quasi-anonymous and whether having multiple identities was possible or whether technical or logistical measures (e.g., cookies, email confirmation, phone calls) were used to detect/prevent these.

| | 1 | 2 | 3 | 4 | 5 | |
|------------------------------|---|---|---|---|---|-----------|
| subitem not at all important | 0 | 0 | 0 | 0 | 0 | essential |

Does your paper address subitem 4a-ii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes - 'Eligible participants were invited to access the web-based trial portal containing trial assessments and intervention and control programs. Participants were required to create an account in the portal using an email address and password and then complete a brief baseline questionnaire. Following the completion of baseline measures, participants were automatically randomized, without involvement by trial staff, to receive the active intervention (FitMindKit) or the attention control program (HealthWatch). Randomization was in a 1:1 allocation ratio by computer-generated sequence, with a block size of 6 stratified by age, sex, and DQ5 severity score, and the trial was double blinded. Following randomization, participants were provided with access to their assigned program and instructed to complete the program modules at their own pace over a 4-week period. They were also sent an email containing details of their allocated condition and a link to the portal. During the intervention period, participants received an automated weekly email reminding them to engage with their allocated program. Following the 4-week period, participants were sent an email inviting them to complete the postintervention survey. They received 2 reminder emails if they had not completed the survey after 1 and 2 weeks.



4a-iii) Information giving during recruitment

Information given during recruitment. Specify how participants were briefed for recruitment and in the informed consent procedures (e.g., publish the informed consent documentation as appendix, see also item X26), as this information may have an effect on user self-selection, user expectation and may also bias results.



Does your paper address subitem 4a-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes - 'Advertisements targeted adults aged 18 years and older living in the Australian Capital Territory to match the delivery catchment for the overarching implementation trial. On clicking on the Facebook advertisement, participants were directed to a webpage containing information about the study and questions to obtain their consent to participate.'

4b) Settings and locations where the data were collected


Does your paper address CONSORT subitem 4b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes - 'Participants were recruited through the web between October 2018 and August 2019 via paid social media advertisements on Facebook and Instagram. Advertisements targeted adults aged 18 years and older living in the Australian Capital Territory to match the delivery catchment for the overarching implementation trial.'

4b-i) Report if outcomes were (self-)assessed through online questionnaires

Clearly report if outcomes were (self-)assessed through online questionnaires (as common in web-based trials) or otherwise.



Does your paper address subitem 4b-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes - 'The DQ5

is a measure of psychological distress and consists of 5 items that assess the symptoms of common mental disorders. Participants were asked to endorse the frequency of each item over the last 30 days on a 5-point scale, ranging from never to always, with scores ranging from 5 to 25. In this study, the categories of DQ5 scores were no or low psychological distress (score of 5-7), moderate psychological distress/risk of a mental disorder (score of 8-17), and high-risk/probable clinical symptoms of a mental disorder (score of 18-25). These cut points were selected based on percentiles from existing population-based data [29]. Participants aged 18 years and older and who scored in the moderate risk category (score of 8-17) on the DQ5 were eligible for the trial, as a web-based self-guided mental health program is likely to be the most suitable for this group.'


| 4b-ii) Report how institutional affiliations are displayed Report how institutional affiliations are displayed to potential participants [on ehealth media], as affiliations with prestigious hospitals or universities may affect volunteer rates, use, and reactions with regards to an intervention.(Not a required item – describe only if this may bias results) | | | | | | | |
|--|---|---|---|---|---|-----------|--|
| | 1 | 2 | 3 | 4 | 5 | | |
| subitem not at all important | 0 | 0 | 0 | 0 | 0 | essential | |

Does your paper address subitem 4b-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

5) The interventions for each group with sufficient details to allow replication, including how and when they were actually administered



E

Does your paper address subitem 5-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

'Each FitMindKit module consists of a 2- to 6-minute video in which a series of fictional animated characters introduce concepts of and share their personal experience of one or more mental health problems. Figure 1 depicts FitMindKit characters. A relevant homework activity designed to facilitate practice of the therapeutic technique presented accompanies each video. Participants allocated to FitMindKit condition were able to access all 12 modules over the 4-week trial period. In total, 8 of the modules contained therapeutic techniques based on CBT principles (psychoeducation, getting help and support, cognitive reframing, problem solving, mindfulness, managing relationships, exercise and diet, and sleep hygiene), 2 modules targeted mood (behavioral activation and reducing rumination), 1 module targeted anxiety (exposure), and 1 module targeted suicidality (distress tolerance). Participants were directed to complete the module on psychoeducation first and were then free to choose when and in which order they completed the remaining modules over the 4-week period.' and 'Participants in the attention control condition received a web-based health program called HealthWatch, a 12-module program pertaining to general health rather than mental health, which is not associated with therapeutic reductions in depression. Modules are text based and contain information on respiratory viruses, heart health, microbes, bone health, food hygiene, sun exposure, dietary supplements, kidney health, household burns, allergens, pancreas health, and posture. Participants randomized to the HealthWatch program were able to access the 12 modules over a 4-week period and complete them in any order.

| 5-ii) Describe the history/development process | | | | | | | |
|--|---|---|---|---|---|-----------|--|
| Describe the history/development process of the application and previous formative evaluations (e.g., focus groups, usability testing), as these will have an impact on adoption/use rates and help with interpreting results. | | | | | | | |
| | 1 | 2 | 3 | 4 | 5 | | |
| subitem not at all important | 0 | 0 | 0 | 0 | 0 | essential | |

Does your paper address subitem 5-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

'As outlined in the protocol paper for this RCT [24], our research group has developed the FitMindKit program, a self-guided transdiagnostic web-based program that delivers CBT and other techniques through a series of brief videos and self-directed exercises. The program focuses on reducing both depression and anxiety symptoms using CBT-based content such as cognitive restructuring, problem-solving skills, and relaxation strategies. FitMindKit has been tested previously in an RCT comparing tailored and static versions of the program [25]. In that underpowered trial, there were no significant differences in effectiveness or adherence for a tailored version of the program, compared with a static version of the program. Consequently, this RCT tested a simplified static version of the program against an attention-matched control condition. This study was nested within a broader implementation study examining the uptake and reach of FitMindKit delivered directly to users through web-based advertising, in comparison with 2 community settings: primary care practices and pharmacies. The web-based arm of the implementation study is the focus of this paper, which used an RCT to test the effectiveness of the intervention in reducing depression symptoms.

5-iii) Revisions and updating

Revisions and updating. Clearly mention the date and/or version number of the application/intervention (and comparator, if applicable) evaluated, or describe whether the intervention underwent major changes during the evaluation process, or whether the development and/or content was "frozen" during the trial. Describe dynamic components such as news feeds or changing content which may have an impact on the replicability of the intervention (for unexpected events see item 3b).



Does your paper address subitem 5-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

'As outlined in the protocol paper for this RCT [24], our research group has developed the FitMindKit program, a self-guided transdiagnostic web-based program that delivers CBT and other techniques through a series of brief videos and self-directed exercises. The program focuses on reducing both depression and anxiety symptoms using CBT-based content such as cognitive restructuring, problem-solving skills, and relaxation strategies. FitMindKit has been tested previously in an RCT comparing tailored and static versions of the program [25]. In that underpowered trial, there were no significant differences in effectiveness or adherence for a tailored version of the program, compared with a static version of the program. Consequently, this RCT tested a simplified static version of the program against an attention-matched control condition. This study was nested within a broader implementation study examining the uptake and reach of FitMindKit delivered directly to users through web-based advertising, in comparison with 2 community settings: primary care practices and pharmacies. The web-based arm of the implementation study is the focus of this paper, which used an RCT to test the effectiveness of the intervention in reducing depression symptoms.

8

5-iv) Quality assurance methods

Provide information on quality assurance methods to ensure accuracy and quality of information provided [1], if applicable.


| | 1 | 2 | 3 | 4 | 5 | |
|------------------------------|---|---|---|---|---|-----------|
| subitem not at all important | 0 | 0 | 0 | 0 | 0 | essential |

https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?hl=en_US&formkey=dGIKd2Z2Q1INSGQ0THI1azM5MS1aWWc6MA&rm=full#g... 39/86

Does your paper address subitem 5-iv?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

'The effectiveness of the FitMindKit intervention was assessed using mixed model repeated-measures (MMRM) analyses of variance (ANOVA) [37] to compare mean scores on the outcome measures between the intervention and control groups. The critical test of effectiveness is the interaction between condition (intervention vs control) and time (posttest vs baseline). MMRM provides an intention-to-treat analysis, with unbiased estimates that account for all available data from participants who were enrolled in the trial [37]. An unstructured variance-covariance matrix was assumed, and df were estimated with Satterthwaite correction. The primary outcome was depression symptoms (PHQ-9) at the posttest end point. Alpha was set at P<.05 for MMRM analyses. Evidence for moderation of outcomes by gender, age group, educational attainment, and module completion was tested using MMRM analyses with three-way interactions of moderator×time×condition. Alpha was set at P<.01 for moderation analyses to account for multiple comparisons. Finally, satisfaction was compared across the 2 conditions on the basis of a two-tailed t test.'




Does your paper address subitem 5-v?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

'The effectiveness of the FitMindKit intervention was assessed using mixed model repeated-measures (MMRM) analyses of variance (ANOVA) [37] to compare mean scores on the outcome measures between the intervention and control groups. The critical test of effectiveness is the interaction between condition (intervention vs control) and time (posttest vs baseline). MMRM provides an intention-to-treat analysis, with unbiased estimates that account for all available data from participants who were enrolled in the trial [37]. An unstructured variance-covariance matrix was assumed, and df were estimated with Satterthwaite correction. The primary outcome was depression symptoms (PHQ-9) at the posttest end point. Alpha was set at P<.05 for MMRM analyses. Evidence for moderation of outcomes by gender, age group, educational attainment, and module completion was tested using MMRM analyses with three-way interactions of moderator×time×condition. Alpha was set at P<.01 for moderation analyses to account for multiple comparisons. Finally, satisfaction was compared across the 2 conditions on the basis of a two-tailed t test.'

5-vi) Digital preservation

Digital preservation: Provide the URL of the application, but as the intervention is likely to change or disappear over the course of the years; also make sure the intervention is archived (Internet Archive, <u>webcitation.org</u>, and/or publishing the source code or screenshots/videos alongside the article). As pages behind login screens cannot be archived, consider creating demo pages which are accessible without login.



Does your paper address subitem 5-vi?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

N/A The intervention is not currently publicly available.

5-vii) Access

Access: Describe how participants accessed the application, in what setting/context, if they had to pay (or were paid) or not, whether they had to be a member of specific group. If known, describe how participants obtained "access to the platform and Internet" [1]. To ensure access for editors/reviewers/readers, consider to provide a "backdoor" login account or demo mode for reviewers/readers to explore the application (also important for archiving purposes, see vi).



Does your paper address subitem 5-vii?*


Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

'Participants were recruited through the web between October 2018 and August 2019 via paid social media advertisements on Facebook and Instagram. Advertisements targeted adults aged 18 years and older living in the Australian Capital Territory to match the delivery catchment for the overarching implementation trial. On clicking on the Facebook advertisement, participants were directed to a webpage containing information about the study and questions to obtain their consent to participate. At this point, participants were assessed for eligibility as described in the following section, Eligibility Criteria. Following eligibility screening, a baseline assessment was completed, followed by randomization and treatment allocation, and a postintervention assessment following the 4-week intervention period.'

https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?hl=en_US&formkey=dGlKd2Z2Q1INSGQ0TH1azM5MS1aWWc6MA&rm=full#g... 45/86

5-viii) Mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework

Describe mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework [6] used to design them (instructional strategy [1], behaviour change techniques, persuasive features, etc., see e.g., [7, 8] for terminology). This includes an in-depth description of the content (including where it is coming from and who developed it) [1]," whether [and how] it is tailored to individual circumstances and allows users to track their progress and receive feedback" [6]. This also includes a description of communication delivery channels and – if computer-mediated communication is a component – whether communication was synchronous or asynchronous [6]. It also includes information on presentation strategies [1], including page design principles, average amount of text on pages, presence of hyperlinks to other resources, etc. [1].



Does your paper address subitem 5-viii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes - see answer to 5i and 5iii.

'Active Transdiagnostic Self-Guided Intervention:

FitMindKit


Each FitMindKit module consists of a 2- to 6-minute video in which a series of fictional animated characters introduce concepts of and share their personal experience of one or more mental health problems. Figure 1 depicts FitMindKit characters. A relevant homework activity designed to facilitate practice of the therapeutic technique presented accompanies each video. Participants allocated to FitMindKit condition were able to access all 12 modules over the 4-week trial period. In total, 8 of the modules contained therapeutic techniques based on CBT principles (psychoeducation, getting help and support, cognitive reframing, problem solving, mindfulness, managing relationships, exercise and diet, and sleep hygiene), 2 modules targeted mood (behavioral activation and reducing rumination), 1 module targeted anxiety (exposure), and 1 module targeted suicidality (distress tolerance). Participants were directed to complete the module on psychoeducation first and were then free to choose when and in which order they completed the remaining modules over the 4-week period.

and

Attention Control Condition: Healthwatch Participants in the attention control condition received a web-based health program called HealthWatch, a 12-module program pertaining to general health rather than mental health, which is not associated with therapeutic reductions in depression. Modules are text based and contain information on respiratory viruses, heart health, microbes, bone health, food hygiene, sun exposure, dietary supplements, kidney health, household burns, allergens, pancreas health, and posture. Participants randomized to the HealthWatch program were able to access the 12 modules over a 4-week period and complete them in any order.'

5-ix) Describe use parameters

Describe use parameters (e.g., intended "doses" and optimal timing for use). Clarify what instructions or recommendations were given to the user, e.g., regarding timing, frequency, heaviness of use, if any, or was the intervention used ad libitum.



Does your paper address subitem 5-ix?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

N/A participants were able to choose when they engaged with the intervention or control material

5-x) Clarify the level of human involvement

Clarify the level of human involvement (care providers or health professionals, also technical assistance) in the e-intervention or as co-intervention (detail number and expertise of professionals involved, if any, as well as "type of assistance offered, the timing and frequency of the support, how it is initiated, and the medium by which the assistance is delivered". It may be necessary to distinguish between the level of human involvement required for the trial, and the level of human involvement required for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

| | 1 | 2 | 3 | 4 | 5 | |
|------------------------------|---|---|---|---|---|-----------|
| subitem not at all important | 0 | 0 | 0 | 0 | 0 | essential |


Does your paper address subitem 5-x?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

N/A the intervention was self-guided and there was no human involvement

5-xi) Report any prompts/reminders used

Report any prompts/reminders used: Clarify if there were prompts (letters, emails, phone calls, SMS) to use the application, what triggered them, frequency etc. It may be necessary to distinguish between the level of prompts/reminders required for the trial, and the level of prompts/reminders for a routine application outside of a RCT setting (discuss under item 21 – generalizability).



Does your paper address subitem 5-xi? *


Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes - 'During the intervention period,

participants received an automated weekly email reminding them to engage with their allocated program. Following the 4-week period, participants were sent an email inviting them to complete the postintervention survey. They received 2 reminder emails if they had not completed the survey after 1 and 2 weeks.'

5-xii) Describe any co-interventions (incl. training/support)

Describe any co-interventions (incl. training/support): Clearly state any interventions that are provided in addition to the targeted eHealth intervention, as ehealth intervention may not be designed as stand-alone intervention. This includes training sessions and support [1]. It may be necessary to distinguish between the level of training required for the trial, and the level of training for a routine application outside of a RCT setting (discuss under item 21 – generalizability.



Does your paper address subitem 5-xii? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No co-interventions

6a) Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed




Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes - see 'Outcome measures'


6a-i) Online questionnaires: describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed

If outcomes were obtained through online questionnaires, describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed [9].



Does your paper address subitem 6a-i? Copy and paste relevant sections from manuscript text

Yes - see 'Outcome measures'



Does your paper address subitem 6a-ii?

Copy and paste relevant sections from manuscript text

Yes - completion of modules was reported

6a-iii) Describe whether, how, and when qualitative feedback from participants was obtained

Describe whether, how, and when qualitative feedback from participants was obtained (e.g., through emails, feedback forms, interviews, focus groups).



Does your paper address subitem 6a-iii?

Copy and paste relevant sections from manuscript text

Not relevant, no qualitative feedback was obtained

6b) Any changes to trial outcomes after the trial commenced, with reasons

Does your paper address CONSORT subitem 6b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not relevant, there were no changes to trial after its commencement

7a) How sample size was determined

NPT: When applicable, details of whether and how the clustering by care provides or centers was addressed

| 7a-i) Describe whether and how expected attrition was taken into account when calculating the sample size Describe whether and how expected attrition was taken into account when calculating the sample size. | | | | | | | |
|---|---|---|---|---|---|-----------|--|
| | 1 | 2 | 3 | 4 | 5 | | |
| subitem not at all important | 0 | 0 | 0 | 0 | 0 | essential | |

Does your paper address subitem 7a-i?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes - 'The target sample size was 750, based on detecting a moderate effect size of Cohen d of 0.4 at posttest with 90% power, assuming 30% attrition from the trial. It was evident early in the trial that the rates of attrition were much higher than anticipated; however, demand for participation in the trial was also greater than anticipated. Consequently, we exceeded the original target to ensure that the final sample was greater than the 525 required at posttest, allowing us to detect more modest effects.'

7b) When applicable, explanation of any interim analyses and stopping guidelines

Does your paper address CONSORT subitem 7b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not relevant, no interim analyses or stopping guidelines

8a) Method used to generate the random allocation sequence

NPT: When applicable, how care providers were allocated to each trial group

Does your paper address CONSORT subitem 8a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes - 'Randomization was in a 1:1 allocation ratio by a computer-generated sequence, with a block size of 6 stratified by age, sex, and DQ5 severity score, and the trial was double blinded.'

8b) Type of randomisation; details of any restriction (such as blocking and block size)

Does your paper address CONSORT subitem 8b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes - 'Randomization was in a 1:1 allocation ratio by a computer-generated sequence, with a block size of 6 stratified by age, sex, and DQ5 severity score, and the trial was double blinded.'

9) Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned

Does your paper address CONSORT subitem 9? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes - 'Randomization was in a 1:1 allocation ratio by a computer-generated sequence, with a block size of 6 stratified by age, sex, and DQ5 severity score, and the trial was double blinded.' 10) Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions

Does your paper address CONSORT subitem 10? *


Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not relevant, randomization was computer generated

11a) If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how NPT: Whether or not administering co-interventions were blinded to group assignment

11a-i) Specify who was blinded, and who wasn't

Specify who was blinded, and who wasn't. Usually, in web-based trials it is not possible to blind the participants [1, 3] (this should be clearly acknowledged), but it may be possible to blind outcome assessors, those doing data analysis or those administering co-interventions (if any).





Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not relevant

11a-ii) Discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator"

Informed consent procedures (4a-ii) can create biases and certain expectations - discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator".



Does your paper address subitem 11a-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

They did not know - 'Following randomization, participants were provided with access to their assigned program and instructed to complete the program modules at their own pace over a 4-week period. They were also sent an email containing details of their allocated condition and a link to the portal. During the intervention period, participants received an automated weekly email reminding them to engage with their allocated program.'

11b) If relevant, description of the similarity of interventions

(this item is usually not relevant for ehealth trials as it refers to similarity of a placebo or sham intervention to a active medication/intervention)

Does your paper address CONSORT subitem 11b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not relevant

12a) Statistical methods used to compare groups for primary and secondary

outcomes

NPT: When applicable, details of whether and how the clustering by care providers or centers was addressed


Does your paper address CONSORT subitem 12a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not relevant, there was no clustering by care provider or centre

12a-i) Imputation techniques to deal with attrition / missing values

Imputation techniques to deal with attrition / missing values: Not all participants will use the intervention/comparator as intended and attrition is typically high in ehealth trials. Specify how participants who did not use the application or dropped out from the trial were treated in the statistical analysis (a complete case analysis is strongly discouraged, and simple imputation techniques such as LOCF may also be problematic [4]).



Does your paper address subitem 12a-i?*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Adherence is reported on

12b) Methods for additional analyses, such as subgroup analyses and adjusted analyses

Does your paper address CONSORT subitem 12b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

There isn't subgroup analysis

X26) REB/IRB Approval and Ethical Considerations [recommended as subheading under "Methods"] (not a CONSORT item)



Does your paper address subitem X26-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Ethics approval is reported under methods

x26-ii) Outline informed consent procedures

Outline informed consent procedures e.g., if consent was obtained offline or online (how? Checkbox, etc.?), and what information was provided (see 4a-ii). See [6] for some items to be included in informed consent documents.

12345subitem not at all importantOOOOessential


Does your paper address subitem X26-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes - 'On clicking on the Facebook advertisement, participants were directed to a webpage containing information about the study and questions to obtain their consent to participate. At this point, participants were assessed for eligibility as described in the following section, Eligibility Criteria.'

X26-iii) Safety and security procedures

Safety and security procedures, incl. privacy considerations, and any steps taken to reduce the likelihood or detection of harm (e.g., education and training, availability of a hotline)



Does your paper address subitem X26-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes - 'Those in the low-risk category were provided with feedback and resources to access if their symptoms changed. Those in the high-risk category were strongly encouraged to seek help from a health professional and provided contact details for face-to-face, telephone-based, and web-based mental health resources and services.'

Researchers didn't receive any identifying information about participants

RESULTS

13a) For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome

NPT: The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider in each center

Does your paper address CONSORT subitem 13a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes - see figure 2

13b) For each group, losses and exclusions after randomisation, together with reasons

Does your paper address CONSORT subitem 13b? (NOTE: Preferably, this is shown in a CONSORT flow diagram) *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not relevant

13b-i) Attrition diagram

Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in or using the intervention/comparator in each group plotted over time, similar to a survival curve) or other figures or tables demonstrating usage/dose/engagement.

| | 1 | 2 | 3 | 4 | 5 | |
|------------------------------|---|---|---|---|---|-----------|
| subitem not at all important | 0 | 0 | 0 | 0 | 0 | essential |

Does your paper address subitem 13b-i?

Copy and paste relevant sections from the manuscript or cite the figure number if applicable (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

14a) Dates defining the periods of recruitment and follow-up

Does your paper address CONSORT subitem 14a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes - 'Participants were recruited through the web between October 2018 and August 2019 via paid social media advertisements on Facebook and Instagram'

and

'Following eligibility screening, a baseline assessment was completed, followed by randomization and treatment allocation, and a postintervention assessment following the 4-week intervention period.'

14a-i) Indicate if critical "secular events" fell into the study period Indicate if critical "secular events" fell into the study period, e.g., significant changes in Internet resources available or "changes in computer hardware or Internet delivery resources" 1 2 3 4 5 subitem not at all important O O O O O O essential

Does your paper address subitem 14a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

14b) Why the trial ended or was stopped (early)

Does your paper address CONSORT subitem 14b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not relevant

15) A table showing baseline demographic and clinical characteristics for each

group

NPT: When applicable, a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group

| Does your paper address | CONSORT subitem 15? * |
|-------------------------|-----------------------|
|-------------------------|-----------------------|

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes - see Table 1

15-i) Report demographics associated with digital divide issues

In ehealth trials it is particularly important to report demographics associated with digital divide issues, such as age, education, gender, social-economic status, computer/Internet/ehealth literacy of the participants, if known.

| | 1 | 2 | 3 | 4 | 5 | |
|------------------------------|---|---|---|---|---|-----------|
| subitem not at all important | 0 | 0 | 0 | 0 | 0 | essential |

Does your paper address subitem 15-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

These details were not known

16) For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups

16-i) Report multiple "denominators" and provide definitions


Report multiple "denominators" and provide definitions: Report N's (and effect sizes) "across a range of study participation [and use] thresholds" [1], e.g., N exposed, N consented, N used more than x times, N used more than y weeks, N participants "used" the intervention/comparator at specific pre-defined time points of interest (in absolute and relative numbers per group). Always clearly define "use" of the intervention.

| | 1 | 2 | 3 | 4 | 5 | |
|------------------------------|---|---|---|---|---|-----------|
| subitem not at all important | 0 | 0 | 0 | 0 | 0 | essential |

Does your paper address subitem 16-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Don't understand this question



Does your paper address subitem 16-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

17a) For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)

Does your paper address CONSORT subitem 17a? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, included

17a-i) Presentation of process outcomes such as metrics of use and intensity of

use

In addition to primary/secondary (clinical) outcomes, the presentation of process outcomes such as metrics of use and intensity of use (dose, exposure) and their operational definitions is critical. This does not only refer to metrics of attrition (13-b) (often a binary variable), but also to more continuous exposure metrics such as "average session length". These must be accompanied by a technical description how a metric like a "session" is defined (e.g., timeout after idle time) [1] (report under item 6a).



Does your paper address subitem 17a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

17b) For binary outcomes, presentation of both absolute and relative effect sizes is recommended

Does your paper address CONSORT subitem 17b? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Not relevant

18) Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory

Does your paper address CONSORT subitem 18?*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Other analyses not performed

18-i) Subgroup analysis of comparing only users

A subgroup analysis of comparing only users is not uncommon in ehealth trials, but if done, it must be stressed that this is a self-selected sample and no longer an unbiased sample from a randomized trial (see 16-iii).

| | 1 | 2 | 3 | 4 | 5 | |
|------------------------------|---|---|---|---|---|-----------|
| subitem not at all important | 0 | 0 | 0 | 0 | 0 | essential |

Does your paper address subitem 18-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

19) All important harms or unintended effects in each group

(for specific guidance see CONSORT for harms)

Does your paper address CONSORT subitem 19? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This was covered in the ethics approval for the trial

| 19-i) Include privacy breaches, technical problems | | | | | | |
|--|-------------|------------|--------------|-------------|------------|-----------|
| Include privacy breaches, technical p but also incidents such as perceived unexpected/unintended incidents. "U | or real pri | vacy bread | ches [1], te | echnical pr | oblems, ar | nd other |
| | 1 | 2 | 3 | 4 | 5 | |
| subitem not at all important | 0 | 0 | 0 | 0 | 0 | essential |

Does your paper address subitem 19-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

19-ii) Include qualitative feedback from participants or observations from

staff/researchers

Include qualitative feedback from participants or observations from staff/researchers, if available, on strengths and shortcomings of the application, especially if they point to unintended/unexpected effects or uses. This includes (if available) reasons for why people did or did not use the application as intended by the developers.



Does your paper address subitem 19-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer


DISCUSSION

22) Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence

NPT: In addition, take into account the choice of the comparator, lack of or partial blinding, and unequal expertise of care providers or centers in each group

22-i) Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use)

Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use).



| Does your paper address subitem 22-i? * Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study |
|--|
| Νο |
| |
| 22-ii) Highlight unanswered new questions, suggest future research Highlight unanswered new questions, suggest future research. |

| | 1 | 2 | 3 | 4 | 5 | |
|------------------------------|---|---|---|---|---|-----------|
| subitem not at all important | 0 | 0 | 0 | 0 | 0 | essential |

Does your paper address subitem 22-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

20) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses

20-i) Typical limitations in ehealth trials

Typical limitations in ehealth trials: Participants in ehealth trials are rarely blinded. Ehealth trials often look at a multiplicity of outcomes, increasing risk for a Type I error. Discuss biases due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events.



Does your paper address subitem 20-i? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes - 'the ecological validity was also a weakness because of the high rates of attrition and low adherence. Adherence was lower in the active condition than in the control condition, which may suggest that the control program may have been less cognitively demanding. Alternatively, the low adherence in the CBT intervention may reflect the challenges of engaging in video content. The analytical method used was robust to attrition, assuming data were missing at random (ie, missing on the basis of the observed characteristics of the sample).'

21) Generalisability (external validity, applicability) of the trial findings

NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial

21-i) Generalizability to other populations

Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations



Does your paper address subitem 21-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

21-ii) Discuss if there were elements in the RCT that would be different in a

routine application setting

Discuss if there were elements in the RCT that would be different in a routine application setting (e.g., prompts/reminders, more human involvement, training sessions or other co-interventions) and what impact the omission of these elements could have on use, adoption, or outcomes if the intervention is applied outside of a RCT setting.

| | 1 | 2 | 3 | 4 | 5 | |
|------------------------------|---|---|---|---|---|-----------|
| subitem not at all important | 0 | 0 | 0 | 0 | 0 | essential |

Does your paper address subitem 21-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

OTHER INFORMATION

23) Registration number and name of trial registry

Does your paper address CONSORT subitem 23? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, number included

24) Where the full trial protocol can be accessed, if available

Does your paper address CONSORT subitem 24? *

Cite a Multimedia Appendix, other reference, or copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, cited.

25) Sources of funding and other support (such as supply of drugs), role of funders

Does your paper address CONSORT subitem 25? *

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes, under Acknowledgements

X27) Conflicts of Interest (not a CONSORT item)

X27-i) State the relation of the study team towards the system being evaluated

In addition to the usual declaration of interests (financial or otherwise), also state the relation of the study team towards the system being evaluated, i.e., state if the authors/evaluators are distinct from or identical with the developers/sponsors of the intervention.

| | 1 | 2 | 3 | 4 | 5 | |
|------------------------------|---|---|---|---|---|-----------|
| subitem not at all important | 0 | 0 | 0 | 0 | 0 | essential |

Does your paper address subitem X27-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Your answer

About the CONSORT EHEALTH checklist

As a result of using this checklist, did you make changes in your manuscript? *

- yes, major changes
- yes, minor changes

) no

What were the most important changes you made as a result of using this checklist?

Your answer

How much time did you spend on going through the checklist INCLUDING making changes in your manuscript *

2 hours

| As a result of using this checklist, do you think your manuscript has improved? * | | | | | |
|---|--|--|--|--|--|
| 🔘 yes | | | | | |
| O no | | | | | |
| • Other: It would have been good to know it was necessary to complete this fo | | | | | |
| Would you like to become involved in the CONSORT EHEALTH group? This would involve for example becoming involved in participating in a workshop and writing an | | | | | |
| "Explanation and Elaboration" document | | | | | |
| () yes | | | | | |
| o no | | | | | |
| O Other: | | | | | |
| Clear selection | | | | | |
| Any other comments or questions on CONSORT EHEALTH | | | | | |
| no | | | | | |

STOP - Save this form as PDF before you click submit

To generate a record that you filled in this form, we recommend to generate a PDF of this page (on a Mac, simply select "print" and then select "print as PDF") before you submit it.

When you submit your (revised) paper to JMIR, please upload the PDF as supplementary file.

Don't worry if some text in the textboxes is cut off, as we still have the complete information in our database. Thank you!

Final step: Click submit !

Click submit so we have your answers in our database!

Submit

Never submit passwords through Google Forms.

This content is neither created nor endorsed by Google. Report Abuse - Terms of Service - Privacy Policy

